Summary of Use during Lactation

No information is available on the use of pegloticase during breastfeeding. Because pegloticase is a very large molecule with molecular weight of 540,000 Da, and composed of smaller subunits with molecular weights of 34,000 Da, the amount in milk is likely to be low. Additionally, the drug is a protein that is likely to be partially digested in the infant’s gastrointestinal tract. It is unlikely that clinically relevant amounts reach the infant’s bloodstream. Studies with other pegylated drugs indicate that polyethylene glycol (PEG) is not excreted into breastmilk. Until more safety data become available, an alternate drug may be preferred.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Pegloticase

CAS Registry Number

885051-90-1

Drug Class

Breast Feeding

Lactation

Antigout Agents

Gout Suppressants